DK2322221T3 - Farmaceutisk sammensætning til behandling og forebyggelse af cancer - Google Patents
Farmaceutisk sammensætning til behandling og forebyggelse af cancerInfo
- Publication number
- DK2322221T3 DK2322221T3 DK09805009.9T DK09805009T DK2322221T3 DK 2322221 T3 DK2322221 T3 DK 2322221T3 DK 09805009 T DK09805009 T DK 09805009T DK 2322221 T3 DK2322221 T3 DK 2322221T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- prevention
- treatment
- pharmaceutical composition
- pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008201928 | 2008-08-05 | ||
JP2009087285 | 2009-03-31 | ||
PCT/JP2009/063882 WO2010016526A1 (ja) | 2008-08-05 | 2009-08-05 | 癌の治療及び予防用医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2322221T3 true DK2322221T3 (da) | 2014-09-01 |
Family
ID=41663743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09805009.9T DK2322221T3 (da) | 2008-08-05 | 2009-08-05 | Farmaceutisk sammensætning til behandling og forebyggelse af cancer |
Country Status (15)
Country | Link |
---|---|
US (4) | US9416192B2 (da) |
EP (1) | EP2322221B1 (da) |
JP (2) | JP5691172B2 (da) |
KR (2) | KR101667319B1 (da) |
CN (2) | CN106039307A (da) |
AU (1) | AU2009278386B2 (da) |
BR (1) | BRPI0911926A2 (da) |
CA (1) | CA2733223C (da) |
DK (1) | DK2322221T3 (da) |
ES (1) | ES2502940T3 (da) |
MX (1) | MX341883B (da) |
PL (1) | PL2322221T3 (da) |
PT (1) | PT2322221E (da) |
RU (1) | RU2498819C2 (da) |
WO (1) | WO2010016526A1 (da) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011001445A (es) * | 2008-08-05 | 2011-04-05 | Toray Industries | Metodo para detectar cancer. |
DK2322221T3 (da) | 2008-08-05 | 2014-09-01 | Toray Industries | Farmaceutisk sammensætning til behandling og forebyggelse af cancer |
US8937160B2 (en) | 2010-02-04 | 2015-01-20 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
RU2567657C2 (ru) * | 2010-02-04 | 2015-11-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
CA2788715C (en) | 2010-02-04 | 2021-06-08 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
DK2532364T3 (da) * | 2010-02-04 | 2016-08-15 | Toray Industries | Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af kræft |
EP2532367B1 (en) * | 2010-02-04 | 2018-08-29 | Toray Industries, Inc. | Pharmaceutical agent for treatment and/or prevention of cancer |
WO2011096534A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
ES2609859T3 (es) | 2011-08-04 | 2017-04-24 | Toray Industries, Inc. | Composición de fármaco para el tratamiento y/o la prevención del cáncer |
RU2624040C2 (ru) | 2011-08-04 | 2017-06-30 | Торэй Индастриз, Инк. | Способ обнаружения рака поджелудочной железы |
MX348579B (es) * | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
US9409993B2 (en) * | 2011-08-04 | 2016-08-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
RU2610428C2 (ru) * | 2011-08-04 | 2017-02-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
HUE047006T2 (hu) * | 2011-08-04 | 2020-04-28 | Toray Industries | Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére |
KR101968499B1 (ko) | 2011-08-04 | 2019-04-12 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
PT2818482T (pt) | 2012-02-21 | 2019-08-06 | Toray Industries | Composição farmacêutica para o tratamento de cancro |
IN2014KN01715A (da) * | 2012-02-21 | 2015-10-23 | Toray Industries | |
WO2013125630A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
ES2739380T3 (es) * | 2012-02-21 | 2020-01-30 | Toray Industries | Composición farmacéutica para el tratamiento del cáncer |
JP6107655B2 (ja) * | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 胆嚢癌の治療及び/又は予防用医薬組成物 |
RU2640245C2 (ru) * | 2012-03-30 | 2017-12-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или предотвращения рака печени |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
HUE043162T2 (hu) * | 2012-07-19 | 2019-08-28 | Toray Industries | Eljárás rák detektálására |
ES2769831T3 (es) | 2012-07-19 | 2020-06-29 | Toray Industries | Método para detectar cáncer |
HUE042081T2 (hu) * | 2013-08-09 | 2019-06-28 | Toray Industries | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére |
EP3043820A4 (en) | 2013-09-13 | 2017-07-12 | F. Hoffmann-La Roche AG | Methods and compositions comprising purified recombinant polypeptides |
RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
CN107530426A (zh) * | 2015-04-30 | 2018-01-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
WO2017170365A1 (ja) * | 2016-03-28 | 2017-10-05 | 東レ株式会社 | 免疫誘導剤 |
US11110179B2 (en) | 2016-06-03 | 2021-09-07 | Seagen Inc. | Combination of CD33 antibody drug conjugates with chemotherapeutic agents |
WO2017214433A1 (en) | 2016-06-09 | 2017-12-14 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with flt3 inhibitors |
CA3029902A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
US20200054762A1 (en) | 2016-10-28 | 2020-02-20 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
WO2019018538A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | RECOMBINANT ANTIBODIES BINDING TO CD123 |
CN110117326B (zh) * | 2018-02-06 | 2022-03-01 | 中国科学院遗传与发育生物学研究所 | 黄腐醇相关蛋白及其在稳定黄腐醇合成途径中产物中的应用 |
BR112020019935A2 (pt) | 2018-03-30 | 2021-01-26 | Toray Industries, Inc. | medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método de tratamento e/ou prevenção do câncer |
CN113993549A (zh) | 2019-03-15 | 2022-01-28 | 博尔特生物治疗药物有限公司 | 靶向her2的免疫缀合物 |
KR20220151684A (ko) | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
BR112022018171A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
WO2021182570A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
KR20220152309A (ko) | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
KR20220152318A (ko) | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
BR112023026985A2 (pt) | 2021-06-23 | 2024-03-12 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agente que aumenta a eficácia do medicamento em uma composição farmacêutica, agente para aumentar a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer |
CN117460532A (zh) | 2021-06-23 | 2024-01-26 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
AU2022316644A1 (en) | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
CA3227706A1 (en) | 2021-07-27 | 2023-02-02 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
CN117693363A (zh) | 2021-07-27 | 2024-03-12 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
US11807685B2 (en) * | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US821163A (en) * | 1905-03-22 | 1906-05-22 | James H Gray | Tumbler for bucket elevators. |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
WO1996009551A1 (en) | 1994-09-19 | 1996-03-28 | Moro Ricardo J | Detection and treatment of cancer |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
HUP0101160A2 (hu) | 1998-04-03 | 2001-08-28 | Chugai Seiyaku Kabushiki Kaisha | Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására |
US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
TR200100916T2 (da) | 1998-07-14 | 2002-06-21 | Corixa@@Corporation | |
GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
EP1187915A2 (en) | 1999-04-02 | 2002-03-20 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
AU1438001A (en) | 1999-10-29 | 2001-05-14 | Human Genome Sciences, Inc. | 27 human secreted proteins |
HUP0500345A2 (hu) | 2000-03-29 | 2005-07-28 | Corixa Corporation | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására |
DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
RU2306952C2 (ru) * | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
WO2002078524A2 (en) | 2001-03-28 | 2002-10-10 | Zycos Inc. | Translational profiling |
WO2002083070A2 (en) * | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
EP1516049A4 (en) | 2001-05-11 | 2006-01-11 | Corixa Corp | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER |
EP1391511B1 (en) | 2001-05-11 | 2008-06-11 | Kirin Pharma Kabushiki Kaisha | Artificial human chromosome containing human antibody lambda light chain gene |
US20030190640A1 (en) * | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
CN1555268B (zh) | 2001-07-17 | 2013-04-03 | 研究发展基金会 | 含促调亡蛋白质的治疗剂 |
RU2319709C2 (ru) | 2001-07-17 | 2008-03-20 | Рисерч Дивелопмент Фаундейшн | Терапевтические агенты, содержащие проапоптозные белки |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
JP2005535290A (ja) | 2002-02-22 | 2005-11-24 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
US20060121029A1 (en) | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
EP2311870A1 (en) | 2002-11-26 | 2011-04-20 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
US20050202451A1 (en) | 2003-04-29 | 2005-09-15 | Burczynski Michael E. | Methods and apparatuses for diagnosing AML and MDS |
EP2481814A3 (en) | 2003-06-09 | 2012-10-10 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
WO2005116076A2 (en) | 2004-01-26 | 2005-12-08 | Debiovision Inc. | Neoplasm-specific polypeptides and their uses |
JP4734319B2 (ja) * | 2004-03-19 | 2011-07-27 | イムクローン・リミテッド・ライアビリティ・カンパニー | ヒト抗上皮成長因子受容体抗体 |
RU2429245C2 (ru) | 2004-03-30 | 2011-09-20 | Глаксо Груп Лимитед | Иммуноглобулины |
WO2005100998A2 (en) * | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
KR101285047B1 (ko) | 2005-01-19 | 2013-07-10 | 제리아 신야쿠 고교 가부시키 가이샤 | 항종양제 |
CA2592177A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
EP1849002A4 (en) | 2005-02-18 | 2008-08-20 | Childrens Medical Center | CYR61 AS A BIOMARKER FOR THE DIAGNOSIS AND PROGNOSIS OF CANCERS OF EPITHELIAL ORIGIN |
WO2006099126A2 (en) | 2005-03-11 | 2006-09-21 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
CN101384273B (zh) | 2006-01-05 | 2013-07-10 | 俄亥俄州立大学研究基金会 | 胰腺内分泌和腺泡肿瘤中的微小rna表达异常 |
CA2642342A1 (en) | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
WO2008073162A2 (en) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Lysine acetylation sites |
US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
JP2009087285A (ja) | 2007-10-03 | 2009-04-23 | Seiko Epson Corp | XML構文解析システム、XML構文解析方法、XML構文解析プログラム、電子機器及びWebサービス |
PT3106874T (pt) | 2007-10-25 | 2020-05-08 | Toray Industries | Método para a deteção de cancro |
JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
CA2990929C (en) | 2008-03-18 | 2022-04-12 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
MX2011001445A (es) | 2008-08-05 | 2011-04-05 | Toray Industries | Metodo para detectar cancer. |
DK2322221T3 (da) | 2008-08-05 | 2014-09-01 | Toray Industries | Farmaceutisk sammensætning til behandling og forebyggelse af cancer |
CN103751771B (zh) | 2008-08-05 | 2017-09-08 | 东丽株式会社 | 免疫诱导剂 |
EA032728B1 (ru) | 2009-08-19 | 2019-07-31 | Мерк Патент Гмбх | Антитела для выявления комплексов интегрина в ffpe материале |
EA026336B1 (ru) | 2009-09-22 | 2017-03-31 | Пробиоген Аг | Клетка позвоночного или насекомого для продукции белка или липида, не содержащего фукозу или содержащего сниженное количество фукозы, и ее применения |
WO2011096534A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
EP2532367B1 (en) | 2010-02-04 | 2018-08-29 | Toray Industries, Inc. | Pharmaceutical agent for treatment and/or prevention of cancer |
RU2567657C2 (ru) | 2010-02-04 | 2015-11-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
DK2532364T3 (da) | 2010-02-04 | 2016-08-15 | Toray Industries | Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af kræft |
CA2788715C (en) | 2010-02-04 | 2021-06-08 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
US8937160B2 (en) | 2010-02-04 | 2015-01-20 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
KR101271964B1 (ko) | 2010-07-08 | 2013-06-07 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
US10533050B2 (en) | 2010-07-26 | 2020-01-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and compositions for liver cancer therapy |
HUE047006T2 (hu) | 2011-08-04 | 2020-04-28 | Toray Industries | Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére |
US9409993B2 (en) | 2011-08-04 | 2016-08-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
RU2624040C2 (ru) | 2011-08-04 | 2017-06-30 | Торэй Индастриз, Инк. | Способ обнаружения рака поджелудочной железы |
KR101968499B1 (ko) | 2011-08-04 | 2019-04-12 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
MX348579B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
ES2609859T3 (es) | 2011-08-04 | 2017-04-24 | Toray Industries, Inc. | Composición de fármaco para el tratamiento y/o la prevención del cáncer |
RU2610428C2 (ru) | 2011-08-04 | 2017-02-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
IN2014KN01715A (da) | 2012-02-21 | 2015-10-23 | Toray Industries | |
ES2739380T3 (es) | 2012-02-21 | 2020-01-30 | Toray Industries | Composición farmacéutica para el tratamiento del cáncer |
PT2818482T (pt) | 2012-02-21 | 2019-08-06 | Toray Industries | Composição farmacêutica para o tratamento de cancro |
WO2013125630A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
RU2640245C2 (ru) | 2012-03-30 | 2017-12-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или предотвращения рака печени |
JP6107655B2 (ja) * | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 胆嚢癌の治療及び/又は予防用医薬組成物 |
ES2769831T3 (es) * | 2012-07-19 | 2020-06-29 | Toray Industries | Método para detectar cáncer |
HUE042081T2 (hu) * | 2013-08-09 | 2019-06-28 | Toray Industries | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére |
US20200054762A1 (en) * | 2016-10-28 | 2020-02-20 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
BR112020019935A2 (pt) * | 2018-03-30 | 2021-01-26 | Toray Industries, Inc. | medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método de tratamento e/ou prevenção do câncer |
KR20220152309A (ko) * | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
BR112022018171A2 (pt) * | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
KR20220151684A (ko) * | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
KR20220152318A (ko) * | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
WO2021182570A1 (ja) * | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
-
2009
- 2009-08-05 DK DK09805009.9T patent/DK2322221T3/da active
- 2009-08-05 KR KR1020167017895A patent/KR101667319B1/ko active IP Right Grant
- 2009-08-05 BR BRPI0911926-4A patent/BRPI0911926A2/pt not_active Application Discontinuation
- 2009-08-05 CN CN201610373466.5A patent/CN106039307A/zh active Pending
- 2009-08-05 PT PT98050099T patent/PT2322221E/pt unknown
- 2009-08-05 EP EP09805009.9A patent/EP2322221B1/en active Active
- 2009-08-05 AU AU2009278386A patent/AU2009278386B2/en active Active
- 2009-08-05 ES ES09805009.9T patent/ES2502940T3/es active Active
- 2009-08-05 KR KR1020117004586A patent/KR101638490B1/ko active IP Right Grant
- 2009-08-05 PL PL09805009T patent/PL2322221T3/pl unknown
- 2009-08-05 CA CA2733223A patent/CA2733223C/en active Active
- 2009-08-05 US US13/057,709 patent/US9416192B2/en active Active
- 2009-08-05 JP JP2009546598A patent/JP5691172B2/ja active Active
- 2009-08-05 MX MX2011001453A patent/MX341883B/es active IP Right Grant
- 2009-08-05 CN CN2009801389599A patent/CN102170907A/zh active Pending
- 2009-08-05 RU RU2011108260/10A patent/RU2498819C2/ru active
- 2009-08-05 WO PCT/JP2009/063882 patent/WO2010016526A1/ja active Application Filing
-
2014
- 2014-11-05 JP JP2014225640A patent/JP5930004B2/ja active Active
-
2016
- 2016-04-06 US US15/092,469 patent/US9982059B2/en active Active
-
2018
- 2018-05-04 US US15/971,647 patent/US20180312603A1/en not_active Abandoned
-
2021
- 2021-02-17 US US17/177,396 patent/US20210188998A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2322221A4 (en) | 2013-02-27 |
US9416192B2 (en) | 2016-08-16 |
RU2011108260A (ru) | 2012-09-10 |
JPWO2010016526A1 (ja) | 2012-01-26 |
JP2015034173A (ja) | 2015-02-19 |
US20210188998A1 (en) | 2021-06-24 |
AU2009278386A1 (en) | 2010-02-11 |
KR101667319B1 (ko) | 2016-10-18 |
EP2322221B1 (en) | 2014-07-09 |
EP2322221A1 (en) | 2011-05-18 |
AU2009278386B2 (en) | 2015-05-21 |
CA2733223C (en) | 2018-02-27 |
KR20110039475A (ko) | 2011-04-18 |
KR20160085372A (ko) | 2016-07-15 |
MX2011001453A (es) | 2011-04-14 |
BRPI0911926A2 (pt) | 2020-08-18 |
JP5691172B2 (ja) | 2015-04-01 |
RU2498819C2 (ru) | 2013-11-20 |
CN102170907A (zh) | 2011-08-31 |
MX341883B (es) | 2016-09-07 |
PT2322221E (pt) | 2014-09-19 |
US20110256144A1 (en) | 2011-10-20 |
PL2322221T3 (pl) | 2015-01-30 |
WO2010016526A1 (ja) | 2010-02-11 |
US9982059B2 (en) | 2018-05-29 |
US20160208014A1 (en) | 2016-07-21 |
JP5930004B2 (ja) | 2016-06-08 |
ES2502940T3 (es) | 2014-10-06 |
US20180312603A1 (en) | 2018-11-01 |
CA2733223A1 (en) | 2010-02-11 |
CN106039307A (zh) | 2016-10-26 |
KR101638490B1 (ko) | 2016-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2322221T3 (da) | Farmaceutisk sammensætning til behandling og forebyggelse af cancer | |
DK2532366T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
DK2155188T3 (da) | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft | |
DK2532680T3 (da) | Medicinsk sammensætning til behandling og/eller forebyggelse af cancer | |
DK2365802T3 (da) | Mikrokapsler af rapamycin og anvendelse til behandling af cancer | |
DK2445489T3 (da) | Sammensætninger til behandling af narkotikamisbrug og forbedring af misbrugsrelateret adfærd | |
DK2154971T3 (da) | Synergistisk farmaceutisk kombination til behandling af cancer | |
DK2340042T3 (da) | Fremgangsmåder og præparater til behandling af cancer | |
DK3351558T3 (da) | Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme | |
DK2894165T3 (da) | Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser | |
DK3878859T3 (da) | Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse | |
DK2220116T3 (da) | Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza | |
BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
DK2653873T3 (da) | Sammensætninger og anvendelser til behandling af multipel sklerose | |
DK2478907T3 (da) | Sammensætninger til behandling af kræft | |
DK3778885T3 (da) | Sammensætninger af udviklede humane arginaser og fremgangsmåder til behandling af cancer | |
DK2114447T3 (da) | Forebyggelse og behandling af subkliniks pcvd | |
DK2398902T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer | |
DK2323638T3 (da) | Sammensætninger og fremgangsmåder til behandling af osteoartritis | |
DK2063881T3 (da) | Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer | |
DK2235002T3 (da) | 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer | |
BRPI0918206A2 (pt) | derivados de animoéster e composição medicinal destes | |
DK3443957T3 (da) | Forbindelser og sammensætninger til behandling af cancer | |
DK2043671T3 (da) | Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber | |
DK2216021T3 (da) | Farmaceutisk sammensætning til behandling af overaktiv blære |